

Our Vision

Empowered by movement, people with spinal cord injuries will enjoy life in the ways that matters to them

Company Profile

ONWARD® Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries (SCI)

ONWARD Medical's work builds on more than a decade of basic science, pre-clinical, and clinical research conducted at the world's leading neuroscience laboratories

Investment Highlights

- Three pioneering neurostimulation platforms designed to address large unmet needs; large potential market (**\$20B+ / €19B**)
- Pivotal trial results published in *Nature Medicine*, May 2024
- Leader in developing Brain Computer Interface (BCI) enabled therapies
- First revenues expected 2H 2024 with ARC^{EX} launch

Note: 1 EUR = 11 USD

ARC Therapy

- Targeted, programmed spinal-cord stimulation to restore movement and other functions in people with spinal cord injury

- Delivered by three purpose-built neuromodulation platforms

ARC^{EX} delivers ARC Therapy™ externally through the skin

ARC^{IM} delivers ARC Therapy via a fully implanted system

ARC^{BCI} pairs ARC^{IM} with an implanted brain-computer interface to restore thought-driven movement via a wireless DigitalBridge™

- 10 FDA Breakthrough Device Designation awards
- Strong and growing IP portfolio with 270+ issued patents¹

¹Includes EP country validations



Note: Investigational devices, not available for commercial use. The ARC^{BCI} graphical representation includes ONWARD Medical's ARC^{IM} with CEA Clinatec's WIMAGINE™ brain-computer interface.

[▶ Watch the video](#)

Pipeline

Platform	Indication	FDA BDD ²	Pre-Clinical	Human PoC	Clinical Feasibility ³	Pivotal
ARC ^{EX}	Upper Limb	✓	○	○	○	○
ARC ^{IM}	Blood Pressure	✓	○	○	○	○ Pivotal expected to start early 2025
ARC ^{IM}	Mobility / Second Indication	✓	○	○	○	○
ARC ^{EX}	Mobility	✓	○	○	○	○
ARC ^{IM}	Parkinson's - Mobility	✓	○	○	○	○
ARC ^{IM}	Bladder	✓	○	○ Human PoC expected in 2025 ⁴	○	○
ARC ^{BCI}	Mobility	✓	○	○	○	○
ARC ^{BCI}	Upper Limb	✓	○	○	○	○
ARC ^{DBS}	Mobility	✓	○	○	○	○

✓ BDD Granted² ○ Current Roadmap ○ Label Expansion ○ Platform Expansion ● Short and medium term focus ○ Funded primarily through grants and research partners

¹Note: The company may modify the pipeline based on clinical progress and marketplace considerations
²BDD = FDA Breakthrough Device Designation. ONWARD has been granted four additional BDDs for ARC^{EX} Bladder, ARC^{EX} Blood Pressure, ARC^{EX} Spasticity and ARC^{EX} Spasticity
³Includes both early feasibility (typically before device design finalized) and feasibility (near-final or final device design) studies
⁴Funded by Christopher & Dana Reeve Foundation grant

Next 12 Months Milestones & News Flow

ARC^{EX}

Up-LIFT pivotal study manuscript publication (Upper Limb)

COMPLETED

ARC^{EX}

Regulatory clearance submission (Upper Limb)

COMPLETED

ARC^{EX}

FDA clearance (Upper Limb)

ARC^{EX}

First commercial sale (Upper Limb – US)

ARC^{IM}

First participant enrollment⁵

Early feasibility study (Parkinson's Mobility)

ARC^{IM}

Interim results publication (Blood Pressure)

ARC^{IM}

IDE submission

Empower BP pivotal study (Blood Pressure)

ARC^{IM}

IDE approval

Empower BP pivotal study (Blood Pressure)

ARC^{IM}

First participant enrollment

Empower BP pivotal study (Blood Pressure)

ARC^{IM}

First-in-human⁶ (Bladder)

ARC^{BCI}

Additional implants⁷ (Upper Limb & Mobility)

Note: All platforms and therapies are for investigational use only

⁵Funded by Michael J. Fox Foundation for Parkinson's Research grant

⁶Funded by Christopher & Dana Reeve Foundation grant

⁷Funded by European Innovation Council and Christopher & Dana Reeve Foundation grants

Key Financial Information

- Successful IPO, October 2021, with strong shareholder base and access to equity capital and debt financing
- Euronext Brussels, Amsterdam and Paris; Ticker Symbol: ONWD; Market Segment: Medtech

- Equity research coverage by Stifel, Bryan, Garnier & Co, KBC Securities, Degroof Petercam and Kepler Cheuvreux

- Cash Position 30 June – €32.1M net cash⁸

Financial Calendar 2024

Note: 1 EUR = 11 USD

⁸Net cash is defined as the sum of cash and cash equivalents and fixed term deposits included in the current assets as included in consolidated statement of financial position in the Financial Statements

About Us

Seasoned Management Team

Dave Marver CEO

Erika Ross Ph.D. VP Clinical,
Regulatory & Quality

Julien Camisani VP Engineering

Sarah Moore VP Global Marketing

Bob Odell VP Operations

Amori Fraser Finance Director

International Presence

~100 FTEs collectively working to create therapies that change lives

Headquartered in the Netherlands, with a science and engineering hub in Switzerland, and a US office in Boston, Massachusetts

Key Partners

- Academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV)
- Christopher and Dana Reeve Foundation is a strategic investor and Michael J. Fox Foundation is a grantor
- Licensing agreements with CEA-Clinathec, Caltech, the University of California, and other leading neuroscience research institutions

This investor fact sheet (the "Fact Sheet") is provided by ONWARD Medical NV (the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and neither the Company nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Fact Sheet.

This Fact Sheet contains forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intent, belief or current expectations, future events, future opportunities for the Company, future planned products and services, business strategy and plans, objectives of management for future operations of the Company, market size and growth opportunities, competitive position, technological and market trends, and other statements that are not historical facts. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," "suggests," "targets," "projects," "forecast" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.

These forward-looking statements are based on the current expectations, beliefs and assumptions of the Company's management and on information currently available to management and are not predictions of actual performance or further results. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date they are made, and the Company assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

This Fact Sheet is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

